Non-small cell lung cancer is most common in older adult smokers and ex-smokers. Small tumors in the lung are often asymptomatic, so the majority of patients have either locally advanced or metastatic disease at diagnosis.
Most common presenting symptoms are cough, chest pain, hemoptysis, dyspnea, and weight loss.
A suspicious lung mass can be biopsied during bronchoscopy or using CT guidance. Staging studies (i.e., CT, PET, mediastinal sampling) are required to determine extent of local or regional disease and to evaluate for metastases.
Treatment depends on stage of disease, histologic subtype, molecular genotype, and patient comorbidities. Treatment modalities include surgery, radiation therapy, and chemotherapy, as well as molecular-targeted therapy for specific genotypes and immunotherapy.
Lung cancer comprises a group of malignant epithelial tumors arising from cells lining the lower respiratory tract. Lung cancer is divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC accounts for more than 80% of all lung cancers. There are three main types of NSCLC (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and these are grouped into further subtypes.
History and exam
- male sex
- pulmonary exam abnormalities
- personality changes
- nausea and vomiting
- bone pain and/or fractures
- weakness, paresthesias, and/or pain in C8/T1 distribution
- cervical or supraclavicular adenopathy
- Horner syndrome
- facial swelling
- dilated neck or chest/abdominal wall veins
- finger clubbing
- hypertrophic pulmonary osteoarthropathy
- sputum cytology
- diagnostic thoracentesis and/or pleural biopsy
- sampling of the mediastinal lymph nodes: mediastinoscopy and endobronchial ultrasound
- video-assisted thoracoscopic surgery (VATS)
- MRI or CT of brain
- MRI of thoracic inlet
- bone scan
- contrast-enhanced CT liver and adrenals
- pulmonary function tests (PFT)
- serum calcium
- electrolytes and renal function
- electrocardiogram and echocardiogram
- epidermal growth factor receptor (EGFR) mutation testing
- anaplastic lymphoma kinase (ALK) testing
- ROS1 testing
- programmed death-ligand 1 (PD-L1) testing
- BRAF testing
- NTRK fusion testing
Professor David R. Baldwin, MD, FRCP
Consultant Respiratory Physician
Nottingham University Hospitals
Honorary Professor of Medicine
University of Nottingham
Respiratory Medicine Unit
David Evans Research Centre
City Hospital Campus
DRB declares that he has no competing interests.
Sanjay Popat, FRCP, PhD
Consultant Medical Oncologist
Department of Medicine
Royal Marsden Hospital
SP has been paid and acted as a consultant to BMS, Eli Lilly, Roche, Takeda, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingelheim, and Tesaro. SP has received research grants from Pierre Fabre, Otsuka, and Boehringer Ingelheim. SP has received assistance for travel from Boehringer Ingelheim, MSD, and Pfizer.
Professor David R. Baldwin and Dr Sanjay Popat would like to gratefully acknowledge Dr Mick Peake, Dr Chris Kelsey, and Dr Lawrence Marks, previous contributors to this topic.
MP has received lecture fees: AstraZeneca Pharmaceuticals, Lilly Oncology Ltd, Pierre-Fabre, GSK Ltd, and Roche Pharmaceuticals Ltd. MP has also received educational grants to attend scientific conferences from Roche Pharmaceuticals Ltd and Boehringer Ingelheim Ltd. CK and LM declare that they have no competing interests.
Alan Neville, MD
AN declares that he has no competing interests.
James Huang, MD
Assistant Attending Surgeon
Memorial Sloan Kettering Cancer Center
JH declares that he has no competing interests.
Siow Ming Lee, PhD, FRCP
Consultant Medical Oncologist
University College Hospital
SML declares that he has no competing interests.
Use of this content is subject to our disclaimer